About Implantica

Company profile

Company profile

Implantica is a privately held medtech company dedicated to bring innovative advances in technology into the body. Medical implants previously seen as unachievable will seek to alleviate unmet medical needs.

IM RefluxStop™

IM RefluxStop™, our CE marked device, will potentially create a paradigm shift in anti-reflux surgery as supported by the clinical trial results. The potential for this product is great as acid reflux is the second largest medical treatment field in the world with 375 million sufferers.1

Implantable eHealth Platform

Implantica plans to bring to the fast expanding eHealth market its sensor implant e-InVivo™, which collects data from inside the body and transfers the data to external devices, such as a watch or directly to the caregiver. e-InVivo™ is designed to monitor a multitude of health parameters and provide diagnostic information as well as control treatment from inside the body. Implantica’s eHealth platform e-InVivo™ is subject to further development and approval process.

Wireless Energising Platform

Implantica’s wireless energising platform, developed for the next generation of “Smart Medical Implants”, is designed to make previously inconceivable medical implants possible. This disruptive technology will power and recharge remote controlled implants wirelessly through intact skin. Implantica’s wireless energising platform is subject to further development and approval process.

The Prioritized Products

Implantica is focusing on two treatment fields: Urology and Gastrointestinal surgery. AppetiteControl™, a new implant to treat obesity by controlling appetite and UriControl®, a remote controlled implant to treat urinary incontinence for both men and women. Implantica’s UriControl® and AppetiteControlTM are subject to further development and approval process.

Extensive Patent Portfolio

Implantica has a large product pipeline supported by an extensive patent portfolio of more than 1’000 patent cases and over 300 inventions covering many applications for our platform technologies.

  1. Stuart 2005